NCRI MUO/CUP Group webinar yesterday (6 May 2021) – Cancers of unknown primary – challenges and opportunities To watch the video on-demand, click here
On 29 April we sponsored a webinar, run by SBK, entitled ‘Enhancing Referral and Management of MUO/CUP Patients’ The webinar was led by Dr Sarah Ngan of GSTT and it can be viewed here.
CUP molecular tumour board – one day virtual event Registration: https://ti.to/gw/cup-symposium-2021
Our friends (see below) in Australia have expanded from the SUPER trial to SUPER-NEXT with funding from the Australian Federal Government. SUPER-NEXT uses state-of-the-art genomics approaches to interrogate the molecular landscape of CUPs. These studies aim to help resolve the cancer tissues of origin, as well as identify potential targeted treatment approaches, providing valuable new information to clinicians to help
Read more
We have been supportive of the concept of RDCs to speed diagnosis for people without obvious primary symptoms. As at Oct 2020 a report from NHS England shows: 34 RDCs are currently live, and a further 60 are in development. In July (most recent available data) RDCs received nearly 900 referrals and diagnosed over 130 cancers. 82% of live pathways
Read more
The 2020/2021 National Genomic Test Directory for cancer specifies the genomic tests commissioned by the NHS in England for cancer, the technology by which they are available, and the patients who will be eligible to access to a test. National Genomic test directory for cancer can be found here. It is then necessary to open an Excel spreadsheet and CUP
Read more
For information about the rollout of Rapid Diagnostic Centres see here
We rely on the excellent stats department of CRUK and the latest available year’s (2017) incidence and mortality data for CUP are shown below: CUP incidence UK total: 8341. About 24 people a day in the UK receive a new CUP diagnosis. It is the 15th most common UK cancer (11th most common in females and 14th most common in
Read more
The Government has launched the new National Genomic Healthcare Strategy – “Genome UK: the future of healthcare” – setting out how the genomics community will come together to harness the latest advances in genetic and genomic science, research, and technology to create the most advanced genomic healthcare system in the world. The Strategy is aimed at driving improvements in healthcare
Read more
The NHS has entered the ‘third phase’ of the pandemic response, effective from 1 August 2020, with the ambition of restoring full operation of all cancer services. The NHS Chief Executive requires Trusts to achieve: • In September at least 80% of their last year’s activity for both overnight electives and for outpatient/day case procedures, rising to 90% in October
Read more